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IL = interleukin; LTB4 = leukotriene B4; RA = rheumatoid arthritis; Tcm = central memory T cells; Teff = effector T cells; TNF = tumour necrosis
factor.
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Unravelling the complex interactions that regulate the
recruitment and subsequent cellular crosstalk between
leukocyte subsets in inflamed synovium offers consider-
able therapeutic potential. In rheumatoid arthritis (RA),
synovial membrane is characterised by T-cell infiltrates
including both CD4 and CD8 subsets that occupy distinct
domains within the tissue [1,2]. The former have attracted
the most attention, given their proposed central role in the
development and maintenance of acquired immune
responses in the synovium. Their functional importance,
however, has been critically reviewed, particularly in light
of equivocal or negative outcomes in clinical trials in which
CD4 T cells have been specifically targeted [1,3,4]. Thus
far, only CTLA4-Ig has shown any clinical promise [5].
Although comprising up to 40% of the synovial T-cell com-
partment, CD8 T cells have received less attention. CD8
T cells are widely distributed throughout the synovial mem-
brane and in synovial fluid, exhibit an activated phenotype
and enhanced migratory activity, express proinflammatory
cytokines, and contribute to formation of ectopic germinal
centres in synovial tissues [1,6,7]. Recruitment of CD8
T cells to the synovial compartment has been considered
a function of appropriate chemokine gradients, lymphocyte
chemokine receptor expression, and activation of endothe-
lial cells, expressing adhesion molecules.
Antigen-experienced CD8 T cells segregate into at least
two populations in mice, namely central memory CD8
T cells (Tcm; CD62Lhi, CCR7hi), which traffic primarily to
lymphoid tissues, and effector memory CD8 T cells (Teff;
CD62lo, CCR7lo), which migrate to nonlymphoid tissues [8].
Distinct populations can be generated in vitro using IL-15
and IL-2 to promote Tcm and Teff populations, respectively.
Whereas CD62L and CCR7 have been attributed homing
function for Tcm, the molecular basis for Teff recruitment to
target tissues has not previously been understood. Ott and
colleagues [9] now report an elegant series of experiments
suggesting that mast-cell-dependent leukotriene B4 (LTB4)
may subserve CD8 Teff recruitment to tissues. Mast-cell
biology has assumed increasing prominence in theories of
synovitis, providing a potential cellular link between humoral
autoimmunity (B cells) and synovial inflammation [10]. The
present observations provide a novel molecular mechanism
for interactions between mast cells and T cells [9].
Using a transwell migration assay, Ott and colleagues
observed that murine CD8 Teff cells but not Tcm cells
migrated in response to soluble factor(s) released by FcεRI-
activated, but not resting, bone-marrow-derived mast cells
[9]. Importantly, migration occurred within minutes of mast-
cell coculture, suggesting release of a preformed or rapidly
synthesised factor. In control experiments, both Tcm and Teff
migrated to CCL5 (RANTES [regulated upon activation,
normal T-cell expressed and secreted]), indicating that Tcm
cells were motile in vitro. Subsequent gene-chip expression
array analysis comparing Tcm and Teff revealed higher
expression of BLT1, a receptor for LTB4, in Teff cells.
Commensurate with a functional role for leukotrienes, the
5-lipoxygenase-activating enzyme inhibitor MK-886 inhibited
mast-cell-induced Teff migration; and purified LTB4, but not
LTC4, directly induced Teff directional migration in a bell-
shaped dose–response curve typical of many chemokines.
In contrast, centrally derived (lymph node) CD122hi Tcm
cells were unable to migrate to LTB4 unless first activated via
the T-cell receptor in the presence of IL-2 to promote a Teff
phenotype. Using the inhibitor CP-105696, LTB4-induced
Teff migration was shown to be dependent on BLT1 (high
affinity) rather than BLT2 (low affinity). Finally, addition of per-
tussis toxin inhibited migration further, implicating BLT1 via
activation of Gi-type G proteins. Together, these data
strongly suggest that a novel function of tissue-activated
mast cells could be to rapidly recruit Teff cells to tissues
during the early phase of innate inflammatory responses.
Mast-cell presence and activation in synovium has been
long described within inflammatory aggregates and adja-
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cent to the cartilage pannus junction, where they may be
associated with cytokine expression [11,12]. Their poten-
tial effector function includes release of proinflammatory
cytokines, chemokines, proteases, vasoactive amines
(e.g. histamine) and arachidonate metabolites, including
prostaglandins and leukotrienes. Mast cells could there-
fore promote downstream activation of mononuclear
cells, chondrocytes, osteoclasts, and angiogenesis [11].
Such functional import has recently been elegantly
demonstrated  in vivo. Administration of serum from
K/B×N mice failed to induce arthritis in Sl/Sld or W/Wv
murine strains, which exhibit functional mast-cell defi-
ciency. Importantly, mast-cell engraftment into W/Wv
recipients recovered the incidence of arthritis following
serum transfer [10]. Therefore, by virtue of FcγR and
complement receptor expression, activated mast cells
could provide a cellular mechanism whereby autoantibod-
ies in the appropriate tissue context could promote host
tissue inflammatory damage.
The data from Ott and colleagues [9] now suggest that
mast cells could significantly modify T-cell function not
only through chemokine release but also via LTB4. Indeed,
since LTB4 is also a potent inducer of neutrophil migration,
these effects may have broader functional importance in
synovium. LTB4 antagonists are effective in reducing colla-
gen- and cytokine-induced arthritis, and 5-LO-deficient
mice exhibit reduced collagen-induced arthritis [13–15].
However, it is currently unclear whether LTB4 occupies a
sufficiently critical hierarchical position in effector mediator
pathways to provide a therapeutic target, given the multi-
plicity of other chemokines present in synovial tissues to
which synovial T cells and indeed other leukocyte subsets
are responsive. Thus, although LTB4 antagonism has
proved to be of some clinical utility in pulmonary inflamma-
tion, it has yet to be properly tested in chronic human syn-
ovitis. Other important issues arise. It would be of interest
to further define CD8 effector subpopulations in RA
tissues and thereafter to determine which are LTB4
responsive. Comparison with migratory activity to other
chemokines prominent in synovial tissues will also be
essential. More difficult is the question of testing the
central role for mast cells in RA in the clinical context.
Whereas mast-cell-focused therapies have not yet been
specifically attempted, cytokine effector pathways includ-
ing tumour necrosis factor α (TNFα) have already proven
amenable to target – mast cells, however, may represent
only a proportion of the TNFα competent cell sources in
synovium. More specific approaches targeting mast-cell
stabilisation or deletion are awaited. As always, the issue
of cellular priority in the chronic, feedback-rich environ-
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